4-fluoro-N-(6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-benzamide | 450366-33-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-fluoro-N-(6,7,8,9-tetrahydro-5H-benzocyclohepten-6-yl)-benzamide
• 英文别名: 4-fluoro-N-(6,7,8,9-tetrahydro-5H-benzo[7]annulen-6-yl)benzamide
• CAS: 450366-33-3
• 化学式: C₁₈H₁₈FNO
• 分子量: 283.345
• InChiKey: QCNJNGNTRWMPNN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical agents
  申请人：——

  公开号：US20030008915A1

  公开（公告）日：2003-01-09

  The present invention relates to compounds according to the general formula (I), 1 wherein R 1 -R 4 have the meanings given in the description, A is CH 2 , CHOH or CH—(C 1 -C 3 -alkyl), B, C and D are independently CH 2 or CH—(C 1 -C 3 -alkyl), and R 5 is an aryl or heteroaryl group, possibly substituted by the substituents listed in the description. These compounds are useful for the manufacture of medicaments for the treatment of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothelial damage after PTCA, hypertension, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes, diabetes complications, nephropathy, retinopathy, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, osteoporosis, or restricted memory performance or for a restricted ability to learn, or the lowering of cardiovascular risk of postmenopausal women or after intake of contraceptives.

  本发明涉及符合一般式（I）的化合物，其中R1-R4具有描述中给出的含义，A为CH2，CHOH或CH-（C1-C3-烷基），B、C和D分别为CH2或CH-（C1-C3-烷基），R5为芳基或杂芳基，可能被描述中列出的取代基取代。这些化合物可用于制造治疗心血管疾病、稳定或不稳定性心绞痛、冠心病、普林兹梅塔尔心绞痛、急性冠状动脉综合征、心力衰竭、心肌梗死、中风、血栓形成、周围动脉闭塞性疾病、内皮功能障碍、动脉粥样硬化、再狭窄、PTCA后内皮损伤、高血压、原发性高血压、肺动脉高压、继发性高血压、肾血管性高血压、慢性肾小球肾炎、勃起功能障碍、室性心律失常、糖尿病、糖尿病并发症、肾病、视网膜病变、血管生成、支气管哮喘、慢性肾功能衰竭、肝硬化、或受限的记忆表现或受限的学习能力，或降低绝经后妇女或口服避孕药后心血管风险的药物。
• ACYLATED 6,7,8,9-TETRAHYDRO-5H-BENZOCYCLOHEPTENYL AMINES AND THEIR USE AS PHARMACEUTICAL
  申请人：Sanofi-Aventis Deutschland GmbH

  公开号：EP1362027B1

  公开（公告）日：2008-05-21
• US6759412B2
  申请人：——

  公开号：US6759412B2

  公开（公告）日：2004-07-06
• US7709478B2
  申请人：——

  公开号：US7709478B2

  公开（公告）日：2010-05-04
• [EN] ACYLATED 6,7,8,9-TETRAHYDRO-5H-BENZOCYCLOHEPTENYL AMINES AND THEIR USE AS PHARMACEUTICAL<br/>[FR] AMINES 6,7,8,9-TETRAHYDRO-5H-BENZOCYCLOHEPTENYL ACYLES ET LEUR UTILISATION COMME PRODUITS PHARMACEUTIQUES
  申请人：AVENTIS PHARMA GMBH

  公开号：WO2002064546A2

  公开（公告）日：2002-08-22

  The present invention relates to compounds according to the general formula (I) wherein RI-R4 have the meanings given in the description, A is CH¿2?, CHOH or CH(C1C3-alkyl) B, C and D are independently CH2 or CH-(C1-C3-alkyl), and R?5¿ is an aryl or heteroaryl group, possibly substituted by the substituents listed in the description. These compounds are useful for the manufacture of medicaments for the treatment of cardiovascular diseases, stable or unstable angina pectoris, coronary heart disease, Prinzmetal angina, acute coronary syndrome, heart failure, myocardial infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, restenosis, endothel damage after PTCA, hypertension, essential hypertension, pulmonary hypertension, secondary hypertension, renovascular hypertension, chronic glomerulonephritis, erectile dysfunction, ventricular arrhythmia, diabetes, diabetes complications, nephropathy, retinopathy, angiogenesis, asthma bronchiale, chronic renal failure, cirrhosis of the liver, osteoporosis, or restricted memory performance or for a restricted ability to learn, or the lowering of cardiovascular risk of postmenopausal women or after intake of contraceptives.